XNAS · ABCL
+10.12% · +$0.6100 · Vol 12.0M
Market closed · last close 4:00 PM ET · price as of 19:59:51 ET
AbCellera Biologics Inc. Common Shares

AbCellera Biologics Inc. Common Shares

PHARMACEUTICAL PREPARATIONS
$6.64

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ABCL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About AbCellera Biologics Inc. Common Shares
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
562
Country
US

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$6.11
Day high
$6.86
Day low
$6.09
Previous close
$6.03
52W high
$6.86
-3.21% from high
52W low
$5.09
88% of range
Market cap
$1.8B
EPS
$-0.6000
Shares out
305.4M
Volume
12M
VWAP
$6.57
Price history computed in-house
1W
+20.07%
SMA 50 $5.57 · above
SMA 200 $5.57 · above
52W position 88%
Veridion warehouse edge

Warehouse intelligence for ABCL.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ABCL insider activity

AbCellera Biologics Inc. Common Shares

Score
Coverage building
Pressure
Net buying
Filings
6
Buys / sells
6 / 0
Net value
$1.2M
Insiders
3
Named filers
BA
Booth Andrew
Insider
Leadership
MS
Montalbano John S.
Insider
Leadership
TL
Thermopylae Holdings Ltd.
Insider
Leadership
Cluster

2 insiders bought in the last 90 days

Net pressure

Net buying: $1.2M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-032026-06-03Booth AndrewInsiderbuy$0.19250,000445,600$48KSEC Form 4
2026-05-182026-05-14Montalbano John S.Insiderbuy$4.7720,000241,000$95KSEC Form 4
2026-03-022026-02-27Thermopylae Holdings Ltd.Insiderbuy$3.4438,00056,134,097$131KSEC Form 4
2026-02-272026-02-27Booth AndrewInsiderbuy$3.4242,600195,600$146KSEC Form 4
2026-02-272026-02-26Thermopylae Holdings Ltd.Insiderbuy$3.27177,45756,096,097$580KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 1 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ABCL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ABCL in this window.
Lobbying spend

ABCL lobbying filings, year to date.

Registered lobbying filings matched to AbCellera Biologics Inc. Common Shares.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ABCL in this window.
Latest news · ABCL
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ABCL.
Options
Sovereign unlock shows live options positioning for ABCL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.